Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by ARNOLD, M. H.
Right arrow Articles by BROOKS, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ARNOLD, M. H.
Right arrow Articles by BROOKS, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1990 British Society for Rheumatology

research-article

COMPARATIVE CONTROLLED TRIAL OF LOW-DOSE WEEKLY METHOTREXATE VERSUS AZATHIOPRINE IN RHUEMATIOD ARTHRITIS: 3-YEAR PROSPECTIVE STUDY

M. H. ARNOLD, J. O'CALLAGHAN, M. McCREDIE, E. M. BELLER, D. E. KELLY and P. M. BROOKS

The Florance and Cope Professional Department of Rheumatology, The Royal North Shore Hospital St Leonards, NSW, 2065, Austrialia

Correspondence to: Correspondence to Prof. P. Brooks.

Fifty-three patients with rheumatoid arthritis who required immunosuppressive therapy were commenced in a randomized trial comparing azathioprine to weekly oral pulse ethotrexate. After an initial 24-week period, both groups had significantly improved from baseline measures of pain and functional capacity and there were no significant ifferences in clinical outcomes between the two groups. Laboratory variables of disease activity showed a significant improvement in haemoglobin and ESR in the methotrexate group. Subsequently, the patients were followed for up to 3 years. After one year, more than half of the patients in both groups had discontinued therapy due to inefficacy or adverse events. Adverse effects were more frequent in the patients treated with ethotrexate, but withdrawal rates were similar in both groups. From these data, the probability of a patient continuing therapy with either agent for reater than 18 months is low.

KEY WORDS: Immunosuppressive treatment, Second-line drugs, Third-line drugs


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DTBHome page
Methotrexate for rheumatoid arthritis
DTB, March 1, 1995; 33(3): 17 - 19.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.